Gland Pharma Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Gland Pharma has a total shareholder equity of ₹87.2B and total debt of ₹3.7B, which brings its debt-to-equity ratio to 4.3%. Its total assets and total liabilities are ₹106.6B and ₹19.4B respectively. Gland Pharma's EBIT is ₹9.3B making its interest coverage ratio 34.7. It has cash and short-term investments of ₹18.4B.
Anahtar bilgiler
4.3%
Borç/özkaynak oranı
₹3.72b
Borç
| Faiz karşılama oranı | 34.7x |
| Nakit | ₹18.39b |
| Eşitlik | ₹87.24b |
| Toplam yükümlülükler | ₹19.37b |
| Toplam varlıklar | ₹106.61b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 543245's short term assets (₹56.5B) exceed its short term liabilities (₹14.0B).
Uzun Vadeli Yükümlülükler: 543245's short term assets (₹56.5B) exceed its long term liabilities (₹5.4B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 543245 has more cash than its total debt.
Borcun Azaltılması: 543245's debt to equity ratio has increased from 0.2% to 4.3% over the past 5 years.
Borç Kapsamı: 543245's debt is well covered by operating cash flow (267.8%).
Faiz Kapsamı: 543245's interest payments on its debt are well covered by EBIT (34.7x coverage).